

# PHARMACODYNAMICS II

## QUANTITATIVE ASPECTS OF DRUGS

Ali Alhoshani, B.Pharm, Ph.D.

[ahoshani@ksu.edu.sa](mailto:ahoshani@ksu.edu.sa)

Office: 2B 84




# Quantitative aspects of drugs



By the end of this lecture, you should:

- Determine quantitative aspects of drug receptor binding.
- Recognize concentration binding curves.
- Identify dose response curves and the therapeutic utility of these curves.
- Classify different types of antagonism.

# QUANTIFY ASPECTS OF DRUG ACTION



Relate concentration [C] of D used (x- axis) to the **binding capacity** at receptors (y-axis)

A Concentration-Binding Curve

Relate concentration [C] of D used (x- axis) to **response** produced (y-axis)

Dose Response Curves


AFFINITY

EFFICACY

POTENCY



# Concentration binding curves

- Is a correlation between drug concentration  $[C]$  used (x-axis) and drug binding capacity at receptors  $[B]$  (y-axis). i.e. relation between concentration & drug binding



# Concentration binding curves

$(B_{max})$ : Total density of receptors in the tissue



$(k_D) = [C]$  of **D** required to occupy 50% of receptors at equilibrium

# Concentration binding curves

- $B_{\max}$  (the binding capacity)
  - ▣ is the total density of receptors in the tissues
- $K_{D50}$ 
  - ▣ is the concentration of drug required to occupy 50% of receptors at equilibrium.
- The affinity of drug for receptor
  - ▣ The higher the affinity of D for receptor the lower is the  $K_D$   
i.e. inverse relation ( Binding Potential =  $B_{\max}/K_D$  )

# Dose -response curves



- Used to study how response varies with the concentration or dose.
- Is a correlation between drug concentration [D] used (x- axis) and drug response [R] (y-axis).
- i.e. relation between concentration & Response

# Dose -response curves



- Type of Dose-response curves
  - ▣ Graded dose-response curve
  - ▣ Quantal dose-response curve (all or none).

# Dose -response curves



- Type of Dose-response curves

- ▣ Graded dose-response curve

- Response is gradual
    - Gradual increase in response by increasing the dose (continuous response).
    - e.g. ↓ blood pressure, heart rate, blood glucose level, cholesterol,...



# Dose -response curves



- Type of Dose-response curves
  - ▣ Graded dose-response curve
    - Curve is usually sigmoid in shape
    - Used to calculate
      - $E_{max}$
      - $EC_{50}$
      - Potency
      - Efficacy

# Dose -response curves- Graded

Max effect =  $E_{max}$  Effect when all the receptors are occupied by D




$EC_{50}$  = C that gives the half-maximal effect

# Dose -response curves

- Dose -response curves- Graded
  - ▣ Used to determine
- **Maximum Efficacy (Emax)**: is the maximal biological response produced by a drug.
- **Median Effective concentration (EC50)**: is the concentration of the drug that gives 50% of the maximal response (Emax).
- **Potency**: the concentration of drug required to produce a specified response (50% of the maximal response = EC50).
- **Potency**: is inversely proportional to EC 50.

# Dose -response curves


## □ Dose -response curves- Graded



# Dose -response curves

- Type of Dose-response curves
  - ▣ Quantal dose-response curve
    - Relate drug concentration to % percentage of patients responding (all or none response).
    - The response may be therapeutic response, adverse effect or lethal effect.
    - e.g. prevention of convulsion, arrhythmias or death.
    - Used to determine
      - ED50
      - TD50 & LD50
      - Therapeutic index.

# Dose -response curves-Quantal



A. 50% of individuals exhibit the specified therapeutic response

B. “ “ “ toxic effects


C. “ “ “ death

*Predict the safety profile*

# Therapeutic Index (T.I.)



- A measure of drug safety
- “The ratio of the dose that produces toxicity to the dose that produces a clinically desired or effective response in a population of individuals”
- Therapeutic Index =  $TD_{50}/ED_{50}$  or  $LD_{50}/ED_{50}$ 
  - $TD_{50}$  is the dose that produces a toxic effect in 50% of the population.
  - $LD_{50}$  is the dose that is lethal in 50% of the population
  - $ED_{50}$  is the dose that produces therapeutic response in 50% of the population
- Large value = drug has wide margin of safety e.g diazepam
- Small value = a narrow margin of safety e.g. digoxin

# Dose -response curves-Quantal



# Therapeutic Index (T.I.)

$$\text{Therapeutic Index: } \frac{LD_{50}}{ED_{50}} = \frac{400}{100} = 4$$





Therapeutic Window



Therapeutic Index

# Therapeutic Index (T.I.)



# Antagonism

- It is the decrease or the complete abolishment of the effect of one drug in the presence of another.
- **Types**
  - Physiological antagonism
  - Chemical antagonism
  - Pharmacokinetic
  - Pharmacodynamic antagonism (Receptor-blockade antagonism).
    - Competitive
      - Reversible
      - Irreversible
    - Non-competitive

# Antagonism

## □ Types

### □ Physiological antagonism

Two drugs act on different receptors to produce different physiological effects. e.g. **Histamine & Adrenaline**

□ **Adrenaline** → Vasoconstriction (↑ BP) & bronchodilation.

□ **Histamine** → vasodilatation (↓ BP) & bronchoconstriction

# Antagonism

---

## □ Types

### □ Chemical antagonism

- Simple chemical reaction & loss of activity
- No receptor.
- e.g. **Dimercaprol** reduces heavy metal toxicity (as in lead toxicity).

# Antagonism

## □ Types

### □ Pharmacokinetic

The antagonist effectively reduces the concentration of the active drug at the site of action.

- e.g. **Phenobarbitone** accelerates hepatic metabolism of warfarin

# Antagonism

## □ Types


□ Pharmacodynamic antagonism (Receptor-blockade antagonism).

■ Competitive

■ Reversible

■ Irreversible

■ Non-Competitive



# Antagonism

- **Types**
  - Pharmacodynamic antagonism (Receptor-blockade antagonism).
    - Competitive
      - Reversible
- Two drugs compete for the same receptor.
- The antagonist partially or completely prevents the pharmacological effect of agonist.
- Antagonist dissociate rapidly from receptor.
- Antagonism can be overcome by increasing the concentration of the agonist.
- Parallel shift of the curve to the right, without any change in slope or maximum
- e.g. acetylcholine and atropine


# Antagonism

## □ Types

□ Pharmacodynamic antagonism (Receptor-blockade antagonism).

■ Competitive

■ Reversible



# Antagonism

## □ Types

- Pharmacodynamic antagonism (Receptor-blockade antagonism).

  - Competitive

    - Irreversible

- Two drugs compete for the same receptor.

- **Antagonist** forms stable, permanent chemical bond with receptor.

- The original response can not be overcome even by increasing the dose of the agonist.

- No parallel shift

- A decrease in slope and a reduced maximum are obtained.



- e.g. **phenoxybenzamine and noradrenaline.**

# Antagonism

Competitive reversible antagonist

vs

Competitive irreversible antagonist



# Antagonism

## □ Types

- Pharmacodynamic antagonism (Receptor-blockade antagonism).
  - Non-Competitive
- Antagonist block at some point the chain of events that stimulate the response of agonist.
- **Agonist** and **Antagonist** can be bound simultaneously.
- Antagonism cannot be overcome by increasing concentration of agonist **e.g. verapamil and noradrenaline.**